Correction to: British Journal of Cancer (2008) 98, 596–603. doi:10.1038/sj.bjc.6604197
Owing to an error on the part of the authors, mistakes were made in the assignment of protein names to the peptides found as biomarkers in the above paper.
The last two graphs in Figure 1 entitled ‘VIM_5’ (lower middle) and ‘VIM_6’ (lower right) should be removed. They are not vimentin-derived peptide signals. The caption of Figure 1B should also be corrected from ‘These six peptide signals’ to ‘These four peptide signals’. Also in the last part of the caption, ‘P<8.3 × 10−6’ should be changed as ‘P<3.8 × 10−7’.
Comparison of the intensity of peptide signals originating from the same protein molecule in each group detected by LC-MS. The vertical axis indicates normalised signal intensity measured by LC-MS. In each box plot, the upper and lower sides of the box represent the upper and the lower quartile values (Q3/Q1), and the upper and lower horizontal bars outside the box indicate the upper and the lower adjacent values (UAV/LAV). Note that UAV is the largest observation value that is less than or equal to Q3+1.5 × (Q3–Q1), and LAV is the smallest observation greater than or equal to Q1–1.5 × (Q3–Q1). Black triangle marks represent the median values, and black square marks represent outliers. U0R0: patients without PAC showing no recurrence within 5 years after surgery. U0R1: patients without PAC showing recurrence within 5 years after surgery. U1R0: patients who received PAC with uracil-tegafur and showed no recurrence within 5 years after surgery. U1R1: patients who received PAC with uracil-tegafur and showed recurrence within 5 years after surgery. (A) These three peptide signals were shown by MS/MS to have originated from myosin IIA. There was a significant difference between the U1R1 and the other groups (P<9.7 × 10−7). (B) These four peptide signals were shown by MS/MS to have originated from vimentin. There was also a significant difference between the U1R1 and the other groups (P<3.8 × 10−7).
In the legend to Figure 3, an error was made in the description of the two graphs (A and B), with the graphs being transposed. The first line of the legend should have read: ‘Kaplan–Meier curves for disease-free survival after complete resection in patients with stage I lung adenocarcinoma who received PAC with uracil-tegafur (B), or did not receive any PAC (A).’
The last two rows of Table 3 should also be removed. The amino-acid sequences assigned as ‘VIM_5’ and ‘VIM_6’ should not be assigned as Vimentin.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/sj.bjc.6604197
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Maeda, J., Hirano, T., Ogiwara, A. et al. Erratum: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualization of postoperative therapy. Br J Cancer 98, 2013–2014 (2008). https://doi.org/10.1038/sj.bjc.6604414
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6604414
